share_log

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target

Benzinga ·  Sep 7, 2023 07:42

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment